scholarly journals Expression features of androgen receptor in special subtypes of breast cancer

2019 ◽  
Author(s):  
Guomin Xiang ◽  
Jing Liu ◽  
Lu Cao ◽  
Cong Xu ◽  
Fang Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Androgen Receptor ◽  
Clinical Work ◽  
Routine Testing ◽  
Positive Expression ◽  
Apocrine Differentiation ◽  
Positive Rate ◽  
Expression Rate ◽  
Medical University

Abstract Purpose The important role of the androgen receptor (AR) in invasive carcinoma of no specific type (NST) has been increasingly recognised. However, only a few studies have been reported in special subtypes of breast cancer. Thus, we aim to investigate the AR expression and its expression features in special subtypes of breast cancer. Methods This study collected clinicopathological data of 718 special subtypes of breast cancer from Tianjin Medical University Cancer Institute and Hospital. Immunohistochemical staining of AR and other biomarkers was performed. Results If the threshold of AR is ≥ 1%, the positive rate of AR in specific subtypes of breast cancer is 77.9% (559/718) of cases. Compared with the threshold of AR is ≥ 10%, the positive percentage of AR in each subtype of breast cancer increases about 10%. The positive expression rate of AR in carcinomas with apocrine differentiation is highest, and the coloration intensity is much stronger than that of other subtypes. The positive expression rate of AR is lowest in metaplastic carcinomas, almost negative; the positive expression rate of AR in invasive lobular carcinomas (ILCs), invasive micropapillary carcinomas (IMPCs), invasive papillary carcinomas (IPCs), and is mucinous carcinomas about 70.0%–80.0%. Conclusions The expression features of AR in special subtypes of breast cancer vary in different subtypes, and to some extent, AR may be a useful biomarker for clinical diagnosis. Routine testing of AR has a certain guiding significance for clinical work. In addition, AR is expected to treat carcinomas with apocrine differentiation as a target.

scholarly journals Antiproliferative Effect of Androgen Receptor Inhibition in Mesenchymal Stem-Like Triple-Negative Breast Cancer

2016 ◽  
Vol 38 (3) ◽  
pp. 1003-1014 ◽  
Author(s):  
Aiyu Zhu ◽  
Yan Li ◽  
Wei Song ◽  
Yumei Xu ◽  
Fang Yang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Androgen Receptor ◽  
Cyclin D1 ◽  
Cancer Cells ◽  
Triple Negative Breast Cancer ◽  
Breast Cancer Cells ◽  
Triple Negative

Background/Aims: Androgen receptor (AR), a steroid hormone receptor, has recently emerged as prognostic and treatment-predictive marker in breast cancer. Previous studies have shown that AR is widely expressed in up to one-third of triple-negative breast cancer (TNBC). However, the role of AR in TNBC is still not fully understood, especially in mesenchymal stem-like (MSL) TNBC cells. Methods: MSL TNBC MDA-MB-231 and Hs578T breast cancer cells were exposed to various concentration of agonist 5-α-dihydrotestosterone (DHT) or nonsteroidal antagonist bicalutamide or untreated. The effects of AR on cell viability and apoptosis were determined by MTT assay, cell counting, flow cytometry analysis and protein expression of p53, p73, p21 and Cyclin D1 were analyzed by western blotting. The bindings of AR to p73 and p21 promoter were detected by ChIP assay. MDA-MB-231 cells were transplanted into nude mice and the tumor growth curves were determined and expression of AR, p73 and p21 were detected by Immunohistochemistry (IHC) staining after treatment of DHT or bicalutamide. Results: We demonstrate that AR agonist DHT induces MSL TNBC breast cancer cells proliferation and inhibits apoptosis in vitro. Similarly, activated AR significantly increases viability of MDA-MB-231 xenografts in vivo. On the contrary, AR antagonist, bicalutamide, causes apoptosis and exerts inhibitory effects on the growth of breast cancer. Moreover, DHT-dependent activation of AR involves regulation in the cell cycle related genes, including p73, p21 and Cyclin D1. Further investigations indicate the modulation of AR on p73 and p21 mediated by direct binding of AR to their promoters, and DHT could make these binding more effectively. Conclusions: Our study demonstrates the tumorigenesis role of AR and the inhibitory effect of bicalutamide in AR-positive MSL TNBC both in vitro and in vivo, suggesting that AR inhibition could be a potential therapeutic approach for AR-positive TNBC patients.

Is it time to consider the Androgen receptor as a therapeutic target in breast cancer?

2021 ◽  
Vol 21 ◽  
Author(s):  
Melika Kooshki Forooshani ◽  
Rosa Scarpitta ◽  
Giuseppe Nicolò Fanelli ◽  
Mario Miccoli ◽  
Antonio Giuseppe Naccarato ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Estrogen Receptor ◽  
Androgen Receptor ◽  
Prognostic Impact ◽  
Nuclear Receptor Superfamily ◽  
Cancer Pathogenesis ◽  
Novel Biomarkers ◽  
Tumorigenic Mechanism

: Breast cancer (BC) is a heterogeneous disease and the most prevalent malignant tumor in women worldwide. The majority of BC cases are positive for estrogen receptor (ER) and progesterone receptor (PgR), both known to be involved in cancer pathogenesis, progression, and invasion. In line with this, hormonal deprivation therapy appears to be a useful tool and an effective treatment for these BC subtypes. Unfortunately, prognosis among patients with hormone-negative tumors or therapy-refractory and metastatic patients remains poor. Novel biomarkers are urgently needed in order to predict the course of the disease, make better therapy decisions and improve the overall survival of patients. In this respect, the androgen receptor (AR), a member of the hormonal nuclear receptor superfamily and ER and PgR, emerges as an interesting feature widely expressed in human BCs. Despite the advances, the precise tumorigenic mechanism of AR and the role of its endogenous ligands are yet not well-understood. In this review, we aim to elaborate on the prognostic impact of AR expression and current AR-targeting approaches based on previous studies investigating AR's role in different BC subtypes.

scholarly journals The role of androgen receptor in breast cancer

2012 ◽  
Vol 9 (1-2) ◽  
pp. e19-e27 ◽  
Author(s):  
Domenico Iacopetta ◽  
Yassine Rechoum ◽  
Suzanne A.W. Fuqua
Keyword(s):  
Breast Cancer ◽  
Androgen Receptor

scholarly journals Prognostic Role of Androgen Receptor Expression in Surgically Resected Early Breast Cancer Patients

2020 ◽  
Vol 23 (2) ◽  
pp. 182 ◽  
Author(s):  
Yaewon Yang ◽  
Ahrum Min ◽  
Kyung-Hun Lee ◽  
Han Suk Ryu ◽  
Tae-Yong Kim ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Androgen Receptor ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Receptor Expression ◽  
Androgen Receptor Expression ◽  
Breast Cancer Patients ◽  
Prognostic Role

scholarly journals Androgen receptor expression predicts breast cancer survival: the role of genetic and epigenetic events

BMC Cancer ◽  
2012 ◽  
Vol 12 (1) ◽  
Author(s):  
Kate M Peters ◽  
Stacey L Edwards ◽  
Shalima S Nair ◽  
Juliet D French ◽  
Peter J Bailey ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Androgen Receptor ◽  
Cancer Survival ◽  
Breast Cancer Survival ◽  
Receptor Expression ◽  
Androgen Receptor Expression ◽  
Epigenetic Events

scholarly journals Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study

Cancers ◽  
2019 ◽  
Vol 11 (7) ◽  
pp. 995 ◽  
Author(s):  
Shristi Bhattarai ◽  
Sergey Klimov ◽  
Karuna Mittal ◽  
Uma Krishnamurti ◽  
Xiaoxian Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Androgen Receptor ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Molecular Subtype ◽  
Good Prognosis ◽  
Prognostic Role ◽  
Primary Tumors ◽  
Total N

Background: The androgen receptor (AR) has emerged as a potential therapeutic target for AR-positive triple-negative breast cancer (TNBC). However, conflicting reports regarding AR’s prognostic role in TNBC are putting its usefulness in question. Some studies conclude that AR positivity indicates a good prognosis in TNBC, whereas others suggest the opposite, and some show that AR status has no significant bearing on the patients’ prognosis. Methods: We evaluated the prognostic value of AR in resected primary tumors from TNBC patients from six international cohorts {US (n = 420), UK (n = 239), Norway (n = 104), Ireland (n = 222), Nigeria (n = 180), and India (n = 242); total n = 1407}. All TNBC samples were stained with the same anti-AR antibody using the same immunohistochemistry protocol, and samples with ≥1% of AR-positive nuclei were deemed AR-positive TNBCs. Results: AR status shows population-specific patterns of association with patients’ overall survival after controlling for age, grade, population, and chemotherapy. We found AR-positive status to be a marker of good prognosis in US and Nigerian cohorts, a marker of poor prognosis in Norway, Ireland and Indian cohorts, and neutral in UK cohort. Conclusion: AR status, on its own, is not a reliable prognostic marker. More research to investigate molecular subtype composition among the different cohorts is warranted.

Investigating and critically appraising the expression and potential role of androgen receptor in breast carcinoma

2011 ◽  
Vol 7 (1) ◽  
Author(s):  
Mark B. Peter ◽  
Abeer M. Shaaban ◽  
Sree Sundara Rajan ◽  
Loaie Maraqa ◽  
Kieran Horgan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Androgen Receptor ◽  
Potential Role ◽  
Prognostic Significance ◽  
Disease Free Survival ◽  
Continuous Variable ◽  
Endocrine Treatment ◽  
Breast Cancer Death

AbstractThe potential role of the androgen receptor (AR) as a predictive or prognostic factor in breast cancer remains unclear. We aimed to determine the prognostic significance of AR in a cohort of breast carcinomas with long-term follow-up and to critically appraise this in the context of existing literature. Four hundred and eight cases of invasive breast cancer were incorporated into tissue microarrays (TMAs). All received tamoxifen and comprised 108 cases which relapsed and 300 cases which did not. Mean follow-up time for the former was 84 months (range 1–142, SD 38.8) and for the latter was 77 months (range 11–229, SD 49.7). TMAs were immunohistochemically stained with AR and scored as a continuous variable and using the Allred score. AR expression was significantly associated with grade, recurrence on tamoxifen, non-breast cancer death estrogen receptor alpha (ERα) and progesterone receptor (PR). AR correlated significantly with better overall survival (OS) and disease-free survival (DFS) using an Allred cut-off of 4 (log rank=0.0053 and 0.0044, respectively), and 20% positive tumor cells (log rank=0.0027 and 0.0059, respectively). AR expression was additionally associated with a reduced risk of recurrence following endocrine therapy. In summary, AR positive breast tumors have better OS and DFS and are less likely to recur following endocrine treatment.

scholarly journals Androgen Receptor Expression Associates With Distinctive Clinicopathological and Molecular Features in ER-Positive and ER-Negative Breast Cancer

2021 ◽  
Author(s):  
Taobo Hu ◽  
Yiqiang Liu ◽  
Guiyang Zhao ◽  
Shu Wang ◽  
Mengping Long
Keyword(s):  
Breast Cancer ◽  
Androgen Receptor ◽  
Clinicopathological Characteristics ◽  
Receptor Expression ◽  
Molecular Features ◽  
Molecular Correlation ◽  
Er Positive ◽  
Er Expression ◽  
Positive Breast Cancer

Abstract Background: Androgen receptor (AR) expression is frequently observed in breast cancer, but its association with estrogen receptor (ER) expression of breast cancer remains unclear. Methods: In this study, we analyzed the clinicopathological and molecular features associated AR loss in ER-positive and ER-negative breast cancer respectively, trying to elucidate the molecular correlation between AR and ER. Results: Our results showed that AR loss was associated with different clinicopathological characteristics in ER-positive and ER-negative breast cancer. Moreover, the expression of AR was correlated with different molecular features in ER-positive and ER-negative breast cancer.Conclusions: These results suggest that the role of AR in ER-positive breast cancer is distinctive from that in ER-negative breast cancer.

scholarly journals Utility of Different Immunohistochemical Stain for Diagnosis of Invasive Breast Cancer

2018 ◽  
Vol 5 (4) ◽  
pp. 3729-3733
Author(s):  
Dujuan Wang ◽  
Li Chen ◽  
Lihua Zeng ◽  
Shuzhen Han
Keyword(s):  
Breast Cancer ◽  
Prognostic Markers ◽  
Clinical Pathology ◽  
Cancer Death ◽  
Breast Cancers ◽  
Immunohistochemical Stain ◽  
Close Relationship ◽  
Positive Rate ◽  
Early Diagnostic

Breast cancer is a malignant tumor that seriously affects females’ physical health, which is the leading cause of cancer death among Chinese female. Estimating early diagnostic and  prognostic markers are helpful to conduct treatment for patients with breast cancer. Accumulating investigations focused on the role of Jab1 and S100A8 proteins in the development and metastasis. In our study, we performed the immunohistochemical stain for Jab1 and S100A8 in breast carcinoma and para-carcinoma samples. We have found that the positive rate of Jab1 and S100A8 in breast cancer was higher than that in para-carcinoma tissues. The expression level of Jab1 and S100A8 in breast cancer might have a close relationship with the histologic grade and lymphatic metastasis. The two proteins might be promising supplementary targets for the treatment and prognosis of breast cancers in clinical pathology.

Sign in / Sign up

Export Citation Format

Share Document